Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35734
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bruno D.L. | en |
dc.contributor.author | Slater H.R. | en |
dc.contributor.author | Whitlam J.B. | en |
dc.contributor.author | Ling L. | en |
dc.contributor.author | Skene A. | en |
dc.contributor.author | Kanellis J. | en |
dc.contributor.author | Ierino F.L. | en |
dc.contributor.author | Power D.A. | en |
dc.date.accessioned | 2021-05-14T12:05:19Z | en |
dc.date.available | 2021-05-14T12:05:19Z | en |
dc.date.copyright | 2019 | en |
dc.date.created | 20190402 | en |
dc.date.issued | 2019-04-02 | en |
dc.identifier.citation | American Journal of Transplantation. 19 (4) (pp 1037-1049), 2019. Date of Publication: April 2019. | en |
dc.identifier.issn | 1600-6135 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/35734 | en |
dc.description.abstract | Graft-derived cell-free DNA (donor-derived cell-free DNA) is an emerging marker of kidney allograft injury. Studies examining the clinical validity of this biomarker have previously used the graft fraction, or proportion of total cell-free DNA that is graft-derived. The present study evaluated the diagnostic validity of absolute measurements of graft-derived cell-free DNA, as well as calculated graft fraction, for the diagnosis of graft dysfunction. Plasma graft-derived cell-free DNA, total cell-free DNA, and graft fraction were correlated with biopsy diagnosis as well as individual Banff scores. Sixty-one samples were included in the analysis. For the diagnosis of antibody mediated rejection, the receiver-operator characteristic area under the curves of graft-derived cell-free DNA and graft fraction were 0.91 (95% CI 0.82-0.98) and 0.89 (95% CI 0.79-0.98), respectively. Both measures did not diagnose borderline or type 1A cellular mediated rejection. Graft fraction was associated with a broader range of Banff lesions, including lesions associated with cellular mediated rejection, while graft-derived cell-free DNA appeared more specific for antibody mediated rejection. Limitations of this study include a small sample size and lack of a validation cohort. The capacity for absolute quantification, and lower barriers to implementation of this methodology recommend it for further study.Copyright © 2018 The American Society of Transplantation and the American Society of Transplant Surgeons | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Blackwell Publishing Ltd | en |
dc.relation.ispartof | American Journal of Transplantation | en |
dc.title | Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction. | en |
dc.type | Article | en |
dc.type.studyortrial | Observational study (cohort, case-control, cross sectional or survey) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/ajt.15142 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 30312536 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30312536] | en |
dc.identifier.source | 624871394 | en |
dc.identifier.institution | (Whitlam, Power) Department of Nephrology, Austin Health, Melbourne, VIC, Australia (Whitlam, Ling, Slater) Cyto-molecular Diagnostics Research Melbourne, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia (Whitlam, Ierino, Power) Department of Medicine, University of Melbourne, Melbourne, VIC, Australia (Skene) Department of Anatomical Pathology, Austin Health, Melbourne, VIC, Australia (Kanellis) Department of Nephrology, Department of Medicine, Monash Health and Centre for Inflammatory Diseases, Monash University, Melbourne, VIC, Australia (Ierino) Department of Nephrology, St Vincent's Health, Melbourne, VIC, Australia (Slater) Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia (Bruno) Victorian Clinical Genetics Services Melbourne, Murdoch Children's Research Institute, Melbourne, VIC, Australia | en |
dc.description.address | J.B. Whitlam, Department of Nephrology, Austin Health, Melbourne, VIC, Australia. E-mail: john.whitlam@austin.org.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2019 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | biomarker clinical research/practice diagnostic techniques and imaging genetics kidney (allograft) function/dysfunction kidney transplantation/nephrology organ transplantation in general rejection rejection: antibody-mediated (ABMR) translational research/science | en |
dc.identifier.authoremail | Whitlam J.B.; john.whitlam@austin.org.au | en |
dc.description.grant | No: 529172731 Organization: *Roche Organ Transplant Research Foundation* Organization No: 501100001258 Country: Switzerland No: GNT1114931 Organization: *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia No: SCH16 141516 Organization: *Kidney Health Australia* Organization No: 501100000975 Country: Australia Organization: *State Government of Victoria* Organization No: 501100004752 Country: Australia | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.